- Ritter Pharmaceuticals - http://www.ritterpharmaceuticals.com -

Microbiome Modulation

Microbiome Modulation

Our microbiome modifiers change and enhance the microbial populations in the gastrointestinal tract in order to improve the health of individuals suffering from gastrointestinal diseases. Microbiome modifiers, or prebiotics, are dietary based gut microbiota management tools that improve health by fortifying beneficial bacteria indigenous to the digestive tract. This technology has expansive promise for the development of numerous products that will treat a variety of conditions and improve digestive health.

The Gut Microbiome

The human gut is a relatively under explored ecosystem, but provides a great opportunity for using dietary intervention strategies to reduce the impact of gastrointestinal disease. The human body carries about 100 trillion microorganisms in the intestines, which is 10 times greater than the number of cells in the human body. This microbial population is responsible for a number of beneficial activities such as fermentation, strengthening the immune system, preventing growth of pathogenic bacteria, providing nutrients, and providing hormones. The increasing knowledge of how these microbial populations impact human health provides opportunities for novel therapies to treat an assortment of diseases such as neurological disease, cardiovascular disease, obesity, irritable bowel syndrome, inflammatory bowel disease, colon cancer, allergies, autism and depression. Recent major initiatives such as the Human Microbiome Project (HMP) by the National Institutes of Health have further validated the significance of the microbial population that exists in our bodies. The increasing knowledge of how these microbial populations impact human health provides opportunities for novel therapies to treat an assortment of diseases.

Research

Publications on the gut microbiome have increased from less than 10 papers annually in 2006 to more than 2,500 papers annually in 2016. Major initiatives such as the Human Microbiome Project by the National Institutes of Health and the Metagenomics Project of the Human Intestinal Tract by the European Commission have further validated the significance of the gut microbiome. The increasing knowledge of how these microbial populations impact human health provides opportunities for novel therapies to treat a number of diseases, including neurological disease, cardiovascular disease, obesity, irritable bowel syndrome, inflammatory bowel disease among others.